Clinical Trial

TheraSphere With Durvalumab and Tremelimumab for HCC

Study acronym: ROWAN
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The objective of the ROWAN clinical study is to assess the efficacy of local tumor control in HCC patients who receive TheraSphere followed by durvalumab and tremelimumab.
Protocol Amendment History 55 amendments
This ClinicalTrials.gov record has been amended 55 times since 2021-09-21; most recent amendment 2026-06-22.
Status change: Recruiting → Active, Not Recruiting 2025-08-21
Status change: Suspended → Recruiting 2023-06-29
Status change: Recruiting → Suspended 2023-02-16
Status change: Not Yet Recruiting → Recruiting 2022-06-14
Trial Details
NCT Number NCT05063565
Lead Sponsor Boston Scientific Corporation
Collaborators: Biocompatibles UK Ltd
Conditions Hepatocellular Carcinoma
Enrollment 100 participants
Start Date 2023-11-03
Primary Completion 2027-06 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-31